Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Smith Discusses CAR T Cells in Multiple Myeloma

Eric Smith, MD, PhD
Published: Tuesday, Mar 28, 2017



Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses chimeric androgen receptor (CAR) T-cell therapy in multiple myeloma.

The target of CAR T-cell therapy in multiple myeloma seems to be anti–B-cell maturation antigen (BCMA), says Smith. The investigational BCMA CAR T-cell therapy bb2121 had an objective response rate of 78% in patients with relapsed/refractory disease, according to interim findings of a phase I dose-escalation study (NCT02658929).

Smith says that next steps are going to include using a fully human CAR to minimize the potential immune responses against CAR.
 


Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses chimeric androgen receptor (CAR) T-cell therapy in multiple myeloma.

The target of CAR T-cell therapy in multiple myeloma seems to be anti–B-cell maturation antigen (BCMA), says Smith. The investigational BCMA CAR T-cell therapy bb2121 had an objective response rate of 78% in patients with relapsed/refractory disease, according to interim findings of a phase I dose-escalation study (NCT02658929).

Smith says that next steps are going to include using a fully human CAR to minimize the potential immune responses against CAR.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: MBCC: Bridging Bench to Bedside: The Potential for Immunotherapeutic Strategies in Breast CancerMay 31, 20192.0
Medical Crossfire®: New Frontiers in the Management of GvHD: Uncovering the Latest Advances to Improve Post-Transplant CareMay 31, 20191.5
Publication Bottom Border
Border Publication
x